References
- Chu K, Dupuy D. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14: 199–208. doi: 10.1038/nrc3672
- Li Y, Wang N, Fan LF, Zhao PF, Li JH, Huang L, et al. Robust electrical impedance tomography for biological application: a mini review. Heliyon 2023; 9: e151195. doi: 10.1016/j.heliyon.2023.e15195
- Zhu FY, Liu W, Li P, Zhao H, Deng X, Wang HL. Electric/magnetic intervention for bone regeneration: a systematic review and network meta-analysis. Tisuue Eng Part B Rev 2023; 29: 217–31. doi: 10.1089/ten.teb.2022.0127
- Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64: 3288–95. doi: 10.1158/0008-5472.CAN-04-0083
- Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhakin F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007; 104: 10152–7. doi: 10.1073/pnas.0702916104
- Kirson ED, Dbalý V, Rochlitz C, Tovaryš F, Salzberg M, Palti Y. Treatment of locally advanced solid tumors using alternating electric fields (TTFields) - a translational study. [abstract]. Proceedings: AACR Annual Meeting 2023; April 14–19, 2023; Orlando, FL; Part 1. Cancer Res 2006; 66(8 Suppl): 1233.
- Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res, 2018; 24: 266–75. doi: 10.1158/1078-0432.CCR-17-1117
- Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis 2009; 26: 633–40. doi: 10.1007/s10585-009-9262-y
- Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci 2013; 1291: 86–95. doi: 10.1111/nyas.12112
- Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48: 2192–202. doi: 10.1016/j.ejca.2012.04.011
- Hottinger AF, Pacheco P, Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol 2016; 18: 1338–49. doi: 10.1093/neuonc/now182
- Leal T, Bueno R, Havel L, Ward J. Tumor treating fields (150 kHz) concurrent with immune check point inhibitors for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR study. [abstract]. J Thorac Oncol 2021; 16: S651. P82.01. doi: 10.1016/j.jtho.2021.01.1192
- Weinberg U, Farber O, Giladi M, Bomzon Z, Kirson ED. Tumor treating field concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase III LUNAR study. [abstract]. ESMO, October 2018. Ann Oncol 2018, 29: viii543. doi: 10.1093/annonc/mdy292.120
- Weinberg U, Farber O, Giladi M, Bomzon Z, Kirson ED. TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): Phase 3 LUNAR study. [abstract]. ESMO, April 2017. Ann Oncol 2017; 28: ii51. doi: 10.1093/annonc/mdx091.065
- Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A Phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer 2013; 81: 445–50. doi: 10.1016/j.lungcan.2013.06.025
- Vergote I, VonMoos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol 2018; 150: 471–7. doi: 10.1016/j.ygyno.2018.07.018
- Picozzi V, Macarulla T, Becerra C, Dragovich T. Front-line treatment of locally advanced pancreatic adenocarcinoma with tumour treating fields concomitant with gemcitabine and nab-paclitaxel: the phase 3 PANOVA-3 study. [abstract]. ESMO, Jun 2022. P-120. Ann Oncol 2022; 33: S292. doi: 10.1016/j.annonc.2022.04.210
- Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopz-Martin J, Kung M. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology 2019; 19: 64–72. doi: 10.1016/j.pan.2018.10.004
- Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology 2014; 14: 54–63. doi: 10.1016/j.pan.2013.11.009
- Leonard F, Kelly J. Clinical value of TTFields treatment in mesothelioma using ASCO and ESMO frameworks. Int J Radiat Oncol Biol Phys 2019; 105: E545–6. doi: 10.1016/j.ijrobp.2019.06.1271
- Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, et al. Tumor treating fields (TTFields) downregulate the Fanconi anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical model. Lung Cancer 2021; 160: 99–110. doi: 10.1016/j.lungcan.2021.08.011.
- Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019; 20: 1702–9. doi: /10.1016/S1470-2045(19)30532-7.
- Grosu A, Touchefeu Y, Brunner T, Gkika E, Thimme R, Cubillo A. Phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): interim safety analysis. [abstract]. P-215. ESMO, Jul 2020. Ann Oncol 2020; 31: S160. doi: 10.1016/j.annonc.2020.04.297
- Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One 2015; 10: 0125269. doi: 10.1371/journal.pone.0125269
- Giladi M, Schneiderman R, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 2015; 5: 18046. doi: 10.1038/srep18046
- Wang XB, Vykoukal J, Becker FF, Gascoyne PRC. Separation of polystyrene microbeads using dielectrophoretic/gravitational field-flow-fractionation. Biophys J 1998; 74: 2689–701. doi: 10.1016/S0006-3495(98)77975-5
- Pethig R. Review article – dielectrophoresis: status of the theory, technology, and applications. Biomicrofluidics 2010; 4: 022811. doi: 10.1063/1.3456626.
- Tuszynski JA, Wenger C, Friesen DE, Preto J. An overview of sub-cellular mechanisms involved in the action of TTFields. Int J Environ Res Public Health 2016; 13: 1128. doi: 10.3390/ijerph13111128
- Li X, Yang F, Rubinsky B. A theoretical study on the biophysical mechanisms by which tumor treating fields affect tumor cells during mitosis. IEEE Trans Biomed Eng 2020; 67: doi: 2594–602. 10.1109/TBME.2020.2965883
- Karanam NK, Ding L, Aroumougame A, Story MD. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. Transl Res 2020; 217: 33–46. doi: 10.1016/j.trsl.2019.10.003
- Kessler A, Frömbling GE, Gross F, Hahn M, Dzokou W, Ernestus RI, et al. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell Death Discov 2018; 4: 77. doi: 10.1038/s41420-018-0079-9
- Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 2009; 9: 1. doi: 10.1186/1756-6649-9-1
- Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci 2007; 104: 10152–7. doi: 10.1073/pnas.0702916104
- Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clinic Oncol 1999; 17: 2572–8. doi: 10.1200/jco.1999.17.8.2572
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J med 2005; 352: 987–96. doi: 10.1056/NEJMoa043330
- Benson L. Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors. Semin Oncol Nurs 2018; 34: 137–50. doi: 10.1016/j.soncn.2018.03.005
- Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 2015; 314: 2535–43. doi: 10.1001/jama.2015.16669
- Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318: 2306–16. doi: 10.1001/jama.2017.18718
- Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893: 1–19. doi: 10.1007/978-3-319-24223-1_1
- Grosso F Mądrzak J, Crinò L, Chella A, Weinberg U, Ceresoli GL. STELLAR – a phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma. J Thorac Oncol 2016; 11: S147–S50. doi: 10.1016/S1556-0864(16)30322-7
- Ceresoli Gl, et al; NovoCure Ltd. Safety and efficacy of TTFields (150 kHz) concomitant with Pemetrexed and cisplatin or carboplatin in malignant pleural mesothelioma (STELLAR). ClinicalTrials.gov. Identifier (NCT number): NCT02397928. Available at:
https://clinicaltrials.gov/ct2/show/NCT02397928?term=NCT+02397928&draw=2&rank=1 - Ceresoli G, Aerts J, Madrzak J, Dziadziuszko R, Ramlau R, Cedres S, et al. STELLAR: final results of a Phase 2 Trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma. [abstract]. VIII641. ESMO, Oct 2018. J Thorac Oncol 2018; 13(Suppl 8): S397–8. doi: 10.1093/annonc/mdy301.001.
- Pless M, et al; NovoCure Ltd. NovoTTF-100L in combination with pemetrexed (Alimta®) for advanced non-small cell lung cancer. ClinicalTrials.gov. Identifier (NCT number): NCT00749346. Available at:
https://clinicaltrials.gov/ct2/show/record/NCT00749346?term=NCT+00749346&draw=2&rank=1 - Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2023; 41: 2682–90. doi: 10.1200/JCO.22.02546
- NovoCure GmbH. Effect of tumor treating fields (TTFields) (150 kHz) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR). ClinicalTrials.gov. Identifier (NCT number): NCT02973789. Available at:
https://clinicaltrials.gov/ct2/show/NCT02973789?term=NCT02973789&draw=2&rank=1 - Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, et al. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer 2016; 139: 2850–8. doi: 10.1002/ijc.30406
- Lok E, San P, White V, Liang O, Widick PC, Reddy SP, et al. Tumor treating fields for ovarian aarcinoma: a modeling study. Adv Radiat Oncol 2021; 6: 100716. doi: 10.1016/j.adro.2021.100716
- Grosso F, Pless M, Ceresoli GL. Safety of tumour treating fields delivery to the torso: meta analysis from TTFields clinical trials. Ann Onco 2019; 30: v187–v8. doi: 10.1093/annonc/mdz244.059
- Kirson ED, Giladi M, Bomzon Z, Weinberg U, Farber O. INNOVATE-3: phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer. J Clin Oncol 2018; 36: TPS5614–TPS5614. doi: 10.1200/JCO.2018.36.15_suppl.TPS5614
- Sessa C, et al; NovoCure Ltd. An open label pilot study of the novoTTF-100L(O) system (NovoTTF Therapy) (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT02244502. Available at:
https://clinicaltrials.gov/ct2/show/NCT02244502?term=TTFields&cond=ovarian+cancer&draw=2&rank=2 - Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 799–808. doi: 10.1016/S1470-2045(14)70244-X
- Vergote I, et al; NovoCure Ltd. Effect of tumor treating fields (TTFields, 200 kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (ENGOT-ov50/GOG-3029/INNOVATE-3). ClinicalTrials.gov. Identifier (NCT number): NCT03940196. Available at:
https://clinicaltrials.gov/ct2/history/NCT03940196?V_82=View#StudyPageTop - Vergote IB, Copeland L, Monk BJ, Coleman RL, Cibula D, Sehouli J, et al. Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase III INNOVATE-3/ENGOT-ov50 study. [abstract]. ESMO, Oct 2019. Ann of Oncol 2019; 30(Suppl 5): v431. doi: 10.1093/annonc/mdz250.067
- Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319–34. doi: 10.1038/nrclinonc.2015.53
- Carbonero RG, Guillen C, Benavides-Orgaz M, Gallego-Plazas J, Rivera F; NovoCure Ltd. A phase II study of TTFields (150 kHz) concomitant with gemcitabine and TTFields concomitant with gemcitabine plus nab-paclitaxel for front-line therapy of advanced pancreatic adenocarcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT01971281. Available at:
https://classic.clinicaltrials.gov/ct2/show/NCT01971281 - NovoCure Ltd. Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT03377491. Available at:
https://clinicaltrials.gov/ct2/show/NCT03377491?term=TTFields&cond=Pancreatic+Adenocarcinoma&draw=2&rank=2 - Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492
- Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, et al. Tumor treating Fields (TTFields) concomitant with sorafenib inhibit hepatocellular carcinoma in iitro and in vivo. Cancers 2022; 14: 2959. doi: 10.3390/cancers14122959
- NovoCure Ltd. HEPANOVA: A Phase II Trial of tumor treating fields (TTFields, 150khz) concomitant with sorafenib for advanced hepatocellular carcinoma (HCC). ClinicalTrials.gov. Identifier (NCT number): NCT03606590. Available at:
https://clinicaltrials.gov/ct2/show/NCT03606590 - Gkikka E, Touchefeu Y, Mercade TM, Gracián AC, Brunner T, Schultheiß M, et al. HEPANOVA: final efficacy and safety results from a phase 2 study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC). [abstract]. IHPBA 15th World Congress. New York, USA, 30 March - 2 April 2022. HPB 2022; 24(Suppl 1): S262–S3. doi: 10.1016/j.hpb.2022.05.551
- Jones TH, Song JW, Abushahin L. Tumor treating fields: an emerging treatment modality for thoracic and abdominal cavity cancers. Transl Oncol 2022; 15: 101296. doi: 10.1016/j.tranon.2021.101296
- Tsimberidou AM et al; MD Anderson Cancer Center. Phase I Study of tumor treating fields (TTF) in combination with cabozantinib, or with atezolizumab and Nab-paclitaxel in patients with advanced solid tumors involving the abdomen or thorax. ClinicalTrials.gov. Identifier (NCT number): NCT05092373. Available at:
https://clinicaltrials.gov/ct2/show/NCT05092373?term=TTFields&cond=Breast+Cancer&draw=2&rank=1 - Tuszynski J, Luchko T, Carpenter E, Crawford E. Results of molecular dynamics computations of the structural and electrostatic properties of tubulin and their consequences for microtubules. J Comput Theor Nanosci 2004; 1: 392–7. doi: 10.1166/jctn.2004.042
- Mershin A, Kolomenski AA, Schuessler HA, Nanopoulos DV. Tubulin dipole moment, dielectric constant and quantum behavior: computer simulations, experimental results and suggestions. Biosystems 2004; 77: 73–85. doi: 10.1016/j.biosystems.2004.04.003
- Mungan CE, Lasinski A. Motion of an electric dipole in a static electromagnetic field. Lat Am J Phys Educ 2008; 2: 192–4.
- Riley MM, San P, Lok E, Swanson KD, Wong ET. The clinical application of tumor treating fields Therapy in Glioblastoma. J Vis Exp 2019; 146: e58937. doi: 10.3791/58937
- Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis 2017; 8: e2753. doi: 10.1038/cddis.2017.171
- Zhao Y, Zhang G. Elucidating the mechanism of 200 kHz tumor treating fields with a modified DEP theory. 2018 IEEE International Symposium on Signal Processing and Information Technology (ISSPIT). 6–8 Dec 2018, Luisville, USA. pp 1–5. doi: 10.1109/ISSPIT.2018.8705145
- Wick W. TTFields: where does all the skepticism come from? Neuro-Oncol 2016; 18: 303–5. doi: 10.1093/neuonc/now012
- Gagliardi LJ. Electrostatic force in prometaphase, metaphase, and anaphase-A chromosome motions. Physi Rev E 2002; 66: 011901. doi: 10.1103/PhysRevE.66.011901
- Gagliardi LJ. Electrostatic force generation in chromosome motions during mitosis. J Electrost 2005; 63: 309–327. doi: 10.1016/j.elstat.2004.09.007
- Gagliardi LJ. Microscale electrostatics in mitosis. J Electrost 2002; 54: 219–32. doi: 10.1016/S0304-3886(01)00155-3
- Stracke R, Böhm KJ, Wollweber L, Tuszynski JA, Unger E. Analysis of the migration behaviour of single microtubules in electric fields. Biochem Biophys Res Commun 2002; 293: 602–9. doi: 10.1016/S0006-291X(02)00251-6
- Zhang Y, Chen X. Blood cells separation microfluidic chip based on dielectrophoretic force. J Braz Soc Mech Sci Eng 2020; 42: 1–11. doi: 10.1007/s40430-020-02284-8
- Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, Tran PT, et al. Tumor treating fields: at the crossroads between physics and biology for cancer treatment. Front Oncol 2020; 10: 575992. doi: 10.3389/fonc.2020.575992
- Alexander S, Rieder CL. Chromosome motion during attachment to the vertebrate spindle: initial saltatory-like behavior of chromosomes and quantitative analysis of force production by nascent kinetochore fibers. J Cell Biol 1991; 113: 805–15. doi: 10.1083/jcb.113.4.805
- Li X, Yang F, Gao B, Yu X, Rubinsky B. A theoretical analysis of the effects of tumor-treating electric fields on single cells. Bioelectromagnetics 2020; 41: 438–46. doi: 10.1002/bem.22274
- Berkelmann L, Bader A, Meshksar S, Dierks A, Hatipoglu Majernik G, Krauss JK, et al. Tumour-treating fields (TTFields): investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis. Sci Rep 2019; 9: 7362. doi: 10.1038/s41598-019-43621-9
- Geng T, Lu C. Microfluidic electroporation for cellular analysis and delivery. Lab Chip 2013; 13: 3803–21. doi: 10.1039/C3LC50566A
- Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov 2018; 4: 113. doi: 10.1038/s41420-018-0130-x
- Kurtz-Nelson EC, Rea HM, Petriceks AC, Hudac CM, Wang T, Earl RK, et al. Alternating electric fields (TTFields) activate Cav1. 2 channels in human glioblastoma cells. Cancers 2019; 11: 110. doi: 10.3390/cancers11010110
- Gal V, Martin S, Bayley P. Fast disassembly of microtubules induced by Mg2+ or Ca2+. Biochem Biophys Res Commun 1988; 155: 1464–1470. doi: 10.1016/S0006-291X(88)81306-8
- Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RSet al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother 2020; 69: 1191–204. doi: 10.1007/s00262-020-02534-7
- Tanzhu G, Chen L, Xiao G, Shi W, Peng H, Chen D, et al. The schemes, mechanisms and molecular pathway changes of tumor treating fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell Death Discov 2022; 8: 416. doi: 10.1038/s41420-022-01206-y
- Chen D, Le SB, Hutchinson TE, Calinescu AA, Sebastian M, Jin D, et al. Tumor treating fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest 2022; 132: e149258. doi: 10.1172/JCI149258
- Shteingauz A, Porat Y, Voloshin T, Schneiderman RS, Munster M, Zeevi E, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTFields). Cell Death Dis 2018; 9: 1074. doi: 10.1038/s41419-018-1085-9
- Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, et al. Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. Oncogene 2019; 38: 6630–46. doi: 10.1038/s41388-019-0882-7
- Lee YJ, Cho JM, Sai S, Oh JY, Park JA, Oh SJ, et al. 5-Fluorouracil as a tumor-treating field-sensitizer in colon cancer therapy. Cancers 2019; 11: 1999. doi: 10.3390/cancers11121999
- Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H, et al. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep 2019; 9: 18699. doi: 10.1038/s41598-019-55296-3